Tissue microarrays from 322 of 374 women in the BR9601 trial , which compared cyclophosphamide , methotrexate , and fluorouracil ( CMF ) with epirubicin followed by CMF ( epi-CMF ) , were analyzed for HER1 , 2 , 3 , 4 ; Ki67 ; and topoisomerase IIalpha protein expression and for HER2/topoisomerase IIalpha gene amplification .
